CLAIMS

1. Use of Isocyclosporin A or an ophthalmically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of an inflammatory and/or autoimmune ophthalmic disease, wherein the medicament is to be administered by topical ophthalmic route.

2. The use as claimed in claim 1, wherein said inflammatory and/or autoimmune ophthalmic disease is selected from corneal and ocular surface inflammatory and/or autoimmune diseases and eyelid margin inflammatory diseases.

3. The use as claimed in claim 1 or claim 2, wherein said corneal and ocular surface inflammatory and/or autoimmune diseases are selected from vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), allergic conjunctivitis, ocular rosacea, uveitis, dry eye disease (DED), ocular cicatricial pemphigoid (OCP), ocular graft-versus-host disease (GVHD) and immune corneal ulcers.

4. The use as claimed in claim 1 or claim 2, wherein said eyelid margin inflammatory diseases are selected from inflamed pterygium and chronic blepharitis.

5. The use as claimed in any one of claims 1 to 4, wherein said salt is selected from acetate, adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate, camphorsulfonate, citrate, cyclohexyl sulfamate, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate, phosphate, diphosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, tosylate (p-toluenesulfonate), trifluoroacetate and undecanoate salts of isocyclosporin A.

6. Ophthalmic formulation comprising isocyclosporin A or an ophthalmically acceptable salt thereof and at least one ophthalmically acceptable excipient or diluent.

7. The ophthalmic formulation as claimed in claim 6, which is a liquid ophthalmic formulation, preferably an eye drop liquid formulation.

8. The ophthalmic formulation as claimed in claim 6, which is a semi-solid ophthalmic formulation, preferably a cream, ointment or gel.

9. The ophthalmic formulation as claimed in claim 6, which is a solid ophthalmic formulation for the extemporaneous preparation of a liquid or semi-solid ophthalmic formulation as claimed in claims 7 or 8, by addition of an ophthalmically acceptable diluent before administration.

10. The ophthalmic formulation as claimed in any one of claims 6 to 8, having a pH comprised between 6 and 8, preferably between 6.4 and 7.8, more preferably between 6.5 and 7.5.

11. Use of the ophthalmic formulation as claimed in any one of claims 6 to 10, in the manufacture of a medicament for the prevention or treatment of an inflammatory and/or autoimmune ophthalmic disease.

12. The use as claimed in claim 11, wherein said inflammatory and/or autoimmune ophthalmic disease is selected from corneal and ocular surface inflammatory and/or autoimmune diseases and eyelid margin inflammatory diseases.

13. The ophthalmic formulation as claimed in any one of claims 6 to 10 further comprising at least one drug suitable for the treatment of inflammatory and/or autoimmune ophthalmic diseases, preferably further comprising a corticosteroid.